Search | Clinical Trials Finder

Conditions: Migraine
Interventions: TEZAMPANEL; Drug
Lead sponsor: TorreyPines Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Familial Hypercholesterolemia - Homozygous
Interventions: Inclisiran, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Boca Raton, Florida

Conditions: Potential Applications for Heart Failure, Volume Overload
Interventions: Two-hour dwell with 10% dextrose in sterile water, Two-hour dwell with Dianeal Low-Calcium with 4.25% Dextrose; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Topical Antisepsis
Interventions: Chlorhexidine gluconate, ChloraPrep One Step, Sterile saline; Drug
Lead sponsor: C. R. Bard; Industry
Eligibility: 16 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Bozeman, Montana

Conditions: Patients With Severe Chronic Kidney Disease Being Evaluated With Nuclear Stress Testing of the Heart Using the Stress Agent Regadenoson
Interventions: Aminophylline, Placebo; Drug
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Infections, Bacterial
Interventions: GSK1322322 (mesylate salt) Powder for Injection, GSK1322322 (freebase) tablets, GSK1322322 (mesylate salt) Powder for Oral Solution, GSK1322322 (freebase) tablets FED; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Stress Urinary Incontinence
Interventions: Cough Stress Test, 24 Hour Pad Test; Procedure · Other
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Orange, California

Conditions: Pain
Interventions: Ethyl Chloride Topical Aerosol Anesthetic, Nature's Tears Sterile Water; Drug
Lead sponsor: Brooke Army Medical Center; Federal
Eligibility: 18 Years to 70 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Fort Sam Houston, Texas

Conditions: Procedural Pain
Interventions: sucrose 24% oral solution, sterile water; Drug
Lead sponsor: Children's Hospital of Michigan; Other
Eligibility: 1 Day to 7 Days
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Mucositis, Pain, Leukemia
Interventions: Real Acupuncture, Sham Acupuncture; Procedure
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Necrotizing Enterocolitis
Interventions: STP206, Control; Biological · Other
Lead sponsor: Leadiant Biosciences, Inc.; Industry
Eligibility: 1 Day to 4 Days
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 13
States / cities: Hartford, Connecticut • Sunrise, Florida • Augusta, Georgia + 10 more

Conditions: Dengue
Interventions: Pre-transfection F17, Post-transfection F17, Post-transfection F19, Placebo; Biological · Other
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 45 Years
Enrollment: 86 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Silver Spring, Maryland

Conditions: HIV Infections
Interventions: Cabotegravir (CAB) tablet, Rilpivirine (RPV) tablet, Cabotegravir - Injectable Suspension (CAB LA), Rilpivirine - Injectable Suspension (RPV LA), ABC/DTG/3TC STR - Tablet, DTG Tablet; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 631 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2029
U.S. locations: 25
States / cities: Birmingham, Alabama • Bakersfield, California • Long Beach, California + 21 more

Conditions: Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions: anti-thymocyte globulin, busulfan, cyclophosphamide, fludarabine phosphate, methotrexate, tacrolimus, nonmyeloablative allogeneic HSCT; Biological · Drug · Procedure
Lead sponsor: Northside Hospital, Inc.; Other
Eligibility: Up to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Healthy
Interventions: 32ppm Silver Particle, Placebo; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 80 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Procedural Pain
Interventions: Administration of oral Sucrose, Administration of oral Placebo; Other
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 3 Months to 11 Months
Enrollment: 98 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Pemphigus
Interventions: Infliximab, Placebo Comparator; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 4
States / cities: Los Angeles, California • Iowa City, Iowa • Durham, North Carolina + 1 more

Conditions: Alcohol Use Disorder (AUD)
Interventions: DCR-AUD, Placebo for DCR-AUD; Drug
Lead sponsor: Dicerna Pharmaceuticals, Inc., a Novo Nordisk company; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Glendale, California

Conditions: Drug Toxicity Psychotropic Agents Psychostimulants
Interventions: Ryanodex (dantrolene sodium) for injectable suspension; Drug
Lead sponsor: Eagle Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Degenerative Lumbar Spinal Stenosis, Degenerative Disc Disease, Degenerative Spondylolisthesis, Degenerative Disease
Interventions: Ropivacaine, Epinephrine, Clonidine, and Ketorolac Injection Cocktail, Placebo; Drug · Other
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 88 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Virus Diseases
Interventions: Danirixin 15 mg FBE, Danirixin 50 mg FBE, Placebo, Oseltamivir 75 mg; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 5
States / cities: Stamford, Connecticut • Council Bluffs, Iowa • Natchitoches, Louisiana + 2 more

Conditions: Venus Leg Ulcers
Interventions: EscharEx (EX-03), Placebo (Gel vehicle); Drug
Lead sponsor: MediWound Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Carlsbad, California

Conditions: Staphylococcal Vaccine
Interventions: Staphylococcus aureus 4-Antigen (SA4Ag) Vaccine, Placebo; Biological · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 3,450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 234
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 89 more

Conditions: Prosthesis-Related Infections, Arthroplasty
Interventions: Betadine Lavage, Saline Lavage; Procedure
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years to 90 Years
Enrollment: 505 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2019
U.S. locations: 2
States / cities: Chicago, Illinois • Winfield, Illinois

Search by objective public record fields.

Study to Assess the Safety, Tolerance and Efficacy of Tezampanel in Patients With Acute Migraine

Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Homozygous Familial Hypercholesterolemia

Zero Sodium Peritoneal Dialysate Protocol Pilot Study

Preoperative Skin Preparation Evaluation

Attenuation of the Side Effect Profile of Regadenoson: Study With Aminophylline in Patients With Severe Kidney Disease Undergoing Myocardial Perfusion Imaging

A Study to Assess the Relative Bioavailability of Three Formulations and Food Effect on GSK1322322 in Healthy Subjects

Is the Cough Stress Test Equivalent to the 24 Hour Pad Test in the Assessment of Stress Incontinence?

Skin Refrigerant to Reduce the Pain Associated With IV Insertion

Skin Blood Flow Changes Using Laser Doppler Imager for Assessment of Pain and Analgesia in Newborn Infants

Acupuncture for Mucositis Pain in Cancer Care

STP206 for the Prevention of Necrotizing Enterocolitis (NEC)

Safety and Immunogenicity of Various Formulations of Live Attenuated Tetravalent Dengue Vaccine in Healthy US Adults

Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants

Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer

In-Vivo Assessment of Silver Biomaterial Nano-Toxicity 32 Ppm

Analgesic Properties of Oral Sucrose During Immunizations

Use of Infliximab for the Treatment of Pemphigus Vulgaris

Study of DCR-AUD in Healthy Volunteers

Efficacy and Safety Study of Ryanodex as Adjuvant Treatment in Subjects With Psychostimulant Drug-Induced Toxicity (PDIT)

Effect of RECK in Posterior Spinal Fusion

Study to Evaluate the Efficacy and Safety of Danirixin Co-administered With Oseltamivir in the Treatment of Adults Hospitalized With Influenza

Clinical Study to Evaluate the Safety and the Efficacy of EscharEx Drug Product (EX-03 Formulation) and Its Placebo Compared to Collagenase, Non-surgical Standard of Care, in Patients With Venous Leg Ulcers

Safety and Efficacy of SA4Ag Vaccine in Adults Having Elective Open Posterior Spinal Fusion Procedures With Multilevel Instrumentation

Dilute Betadine Lavage in the Prevention of Postoperative Infection